Evidence map›Paper›PMID 39732745›Full record

ArticleScientific reports2024

Antifungal activity of essential oils and their potential synergistic effect with amphotericin B.

Xin Yuan, Dan Cao, Yanghui Xiang, Xiuzhi Jiang, Jiaying Liu, Kefan Bi, Xu Dong, Tiantian Wu, Ying Zhang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. [Preparation of Lip-TTO-PHMB and evaluation of itsZhonghua shao shang yu chuang mian xiu fu za zhi · 2026
    Article
  3. Current Knowledge of the GenusPharmaceuticals (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Review
  6. TargetingInternational journal of molecular sciences · 2025
    Article
  7. Unraveling the Effects ofInternational journal of molecular sciences · 2025
    Review
  8. The Potential ofPharmaceutics · 2025
    Article
  9. Article
  10. Article
  11. Antifungal activity and mechanism ofFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin YuanState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Dan CaoState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Yanghui XiangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Xiuzhi JiangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Jiaying LiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Kefan BiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Xu DongState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Tiantian WuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Ying ZhangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China. yzhang207@zju.edu.cn.

Funding

Jinan Microecological Biomedicine Shandong Laboratory project JNL-2022050BNational Infectious Disease Medical Center startup fund (YZ)(B2022011-1)
6 · The paper itself

Abstract

Candida albicans is a common opportunistic pathogen, causing infections ranging from superficial to bloodstream infections. The limited antifungal options and rising drug resistance challenge clinical treatment. We screened 98 essential oils and identified 48 with antifungal activity against Candida albicans at 1% concentration, determining their minimum inhibitory concentrations (MIC). Of these, 14 maintained fungicidal activity at lower concentrations (0.25% and 0.125%). 5 essential oils (Cinnamon, Satureja montana, Palmarosa, Lemon eucalyptus, and Honey myrtle) showed the highest inhibitory effects on stationary-phase Candida albicans and inhibited hyphae elongation. Synergistic effects were observed when combining Palmarosa with amphotericin B (AmB) against growing-phase Candida albicans, while Cinnamon and Satureja montana with AmB showed superior efficacy against stationary-phase infections. We identified the active components of 5 essential oils using gas chromatography-mass spectrometry (GC-MS) and found the following main constituents: Cinnamon primarily contains benzyl benzoate and eugenol, Satureja montana is dominated by carvacrol and cymene, Palmarosa features geraniol and geranyl acetate, Lemon eucalyptus includes dl-Isopulegol and citronellal, and Honey myrtle is characterized by citral and neral. Our results may aid in developing more effective antifungal treatments.

Indexed as

Amphotericin BAntifungal AgentsCandida albicansDrug SynergismMicrobial Sensitivity TestsOils, VolatileCinnamomum zeylanicumCymenesEucalyptusGas Chromatography-Mass SpectrometrySaturejaAmphotericin BAntifungal AgentscarvacrolCymenesOils, VolatileAntimicrobial activityCandida albicansDrug combinationEssential oilsGC-MSStationary phase

Identifiers

PMID39732745
PMCPMC11682416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.